CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04938232
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:29.756592+00:00
- Published At
- 2025-04-03T00:00:00+00:00
- Record Updated At
- 2026-02-05
- Results Posted At
- 2025-04-03
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Hodgkin Lymphoma", "Relapsed Hodgkin\u0027s Disease, Adult", "Refractory Hodgkin Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-05"- protocolSection.identificationModule.nctId
"NCT04938232"- protocolSection.identificationModule.officialTitle
"A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-03"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.